C3 Protein (Complement Component 3)
Overview
C3 Protein (Complement Component 3) is a central hub of the [complement system](/entities/complement-system) and plays a critical role in innate immunity and neuroinflammation. It is one of the most abundant proteins in the complement system and serves as a convergence point for all three complement activation pathways. In the central nervous system, C3 is produced by [neurons](/cell-types/neurons), [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia-neuroinflammation), and [oligodendrocytes](/cell-types/oligodendrocyte-lineage-ad), making it a key mediator of neuroinflammatory processes in neurodegenerative diseases.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">C3 Protein (Complement Component 3)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Complement Component 3 (C3)</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>C3</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P01024" target="_blank">P01024</a></td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~185 kDa (alpha chain: ~110 kDa, beta chain: ~70 kDa)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>[Complement System](/mechanisms/complement-system), Alpha-2-macroglobulin family</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Secreted, plasma, cytoplasm</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>[Neurons](/entities/neurons), [astrocytes](/entities/astrocytes), microglia, oligodendrocytes</td></tr>
<tr><td><strong>Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), [Multiple Sclerosis](/diseases/multiple-sclerosis)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/alzheimers_disease" style="color:#ef9a9a">ALZHEIMERS_DISEASE</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's Disease</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">281 edges</a></td>
</tr>
</table>
</div>
Introduction
Complement Component 3 (C3) is the central molecule of the complement system, a key component of innate immunity. The complement system consists of over 50 proteins that work together to opsonize pathogens, recruit immune cells, and lyse foreign cells. C3 is the most abundant complement protein in plasma and serves as the convergence point for all three complement activation pathways: the classical pathway, the lectin pathway, and the alternative pathway [1].
In the brain, C3 plays a dual role. Under normal conditions, it contributes to synaptic pruning during development, a process by which excess synapses are eliminated to refine neural circuits [2]. However, dysregulated complement activation is implicated in the pathogenesis of multiple neurodegenerative diseases, where excessive complement activation contributes to neuroinflammation, synaptic loss, and progressive neuronal damage [3].
Structure
C3 is a large glycoprotein composed of an alpha chain (~110 kDa) and a beta chain (~70 kDa) linked by disulfide bonds:
Domain Architecture
- CUB domain: Required for proper folding and stability
- Thioester-containing domain (TED): Contains a reactive thioester bond that allows C3b to covalently attach to pathogen surfaces
- Linker domain: Connects TED to the alpha chain
- C345c domain: Found in C3, C4, and C5, involved in protein-protein interactions
- Anaphylatoxin domain (C3a): Released upon activation as a potent inflammatory mediator
Key Structural Features
| Feature | Description |
|---------|-------------|
| Thioester bond | Reactive cysteine-methionine ester that covalently bonds to hydroxyl or amine groups on pathogen surfaces |
| Protease cleavage sites | Multiple sites for factor I-mediated cleavage and downstream complement activation |
| Conformational changes | Dramatic structural rearrangements upon activation expose functional domains |
Alternative Splicing Variants
- C3a: Anaphylatoxin fragment (9 kDa)
- C3b: Opsonin fragment (large fragment after cleavage)
- C3c: Large fragment remaining after further cleavage
- C3d: Fragment involved in immune complex clearance
- C3dg: Cell-bound fragment
Normal Function
Complement Activation Pathways
C3 serves as the central hub for all three complement activation pathways:
Classical Pathway
Initiated by antigen-antibody complexes (C1q binding to IgG/IgM), leading to C1r/C1s activation, which then cleaves C4 and C2 to form the C3 convertase (C4b2a).
Lectin Pathway
Activated by mannose-binding lectin (MBL) or ficolins binding to carbohydrate patterns on pathogens, also leading to C4b2a formation.
Alternative Pathway
Spontaneous C3 tick-over produces C3(H2O), which then binds Factor B. Factor D cleaves Factor B to form the C3 convertase (C3bBb), which can amplify complement activation on surfaces that lack complement regulators.
Key Biological Functions
| Function | Description | Mechanism |
|----------|-------------|-----------|
| Opsonization | Marks pathogens for phagocytosis | C3b covalently attaches to pathogen surfaces |
| Inflammation | Recruits immune cells | C3a anaphylatoxin releases histamine from mast cells |
| Cell lysis | Direct pathogen killing | C5b-9 membrane attack complex formation |
| Immune clearance | Removes immune complexes | C3b/d receptors on erythrocytes and macrophages |
| Synaptic pruning | Developmental refinement | Complement-mediated synapse elimination |
CNS-Specific Functions
In the central nervous system, complement proteins serve specialized functions:
Developmental synaptic pruning: During early development, complement components C1q and C3 tag synapses for elimination by microglia [4]
Axonal guidance: Complement proteins participate in neural circuit formation
Neuroprotection: Low-level complement activation can be neuroprotective
Astrocyte-neuron communication: C3 expressed by astrocytes modulates neuronal function
Role in Neurodegenerative Diseases
Alzheimer's Disease
C3 plays a significant role in Alzheimer's disease pathogenesis through multiple mechanisms:
Amyloid-Beta Pathology
- C3 co-localizes with [amyloid-beta](/proteins/amyloid-beta) plaques in AD brain [5]
- Complement activation accelerates Aβ aggregation and deposition
- C3b opsonization of Aβ enhances microglial phagocytosis but can also trigger chronic inflammation
- The balance between complement activation and inhibition affects Aβ clearance efficiency
Neurofibrillary Tangles
- Complement proteins bind to hyperphosphorylated [tau](/proteins/tau) tangles [6]
- Complement activation may exacerbate [tau](/proteins/tau) pathology propagation
- Neuronal C3 expression is upregulated in tauopathies
Synaptic Loss
- C1q and C3 mediate complement-dependent synaptic elimination in AD [7]
- Early synaptic loss correlates with complement activation
- Microglial complement receptor 3 (CR3) mediates synaptic phagocytosis
Neuroinflammation
- Chronically elevated C3a and C5a anaphylatoxins promote neuroinflammation
- C3a receptor (C3aR) signaling on microglia enhances pro-inflammatory cytokine production
- The neurovascular unit shows complement dysregulation in AD
Parkinson's Disease
In Parkinson's disease, C3 contributes to dopaminergic neuron degeneration:
- C3 is present in [Lewy bodies](/mechanisms/alpha-synuclein-pathology) [8]
- Microglial C3 activation in the substantia nigra [9]
- Complement-mediated inflammation accelerates [alpha-synuclein](/proteins/alpha-synuclein) pathology
- C3a receptor antagonism shows promise in PD models
Amyotrophic Lateral Sclerosis (ALS)
C3 plays a role in motor neuron degeneration:
- Activated microglia produce C3 in ALS spinal cord [10]
- C3 expression is elevated in sporadic and familial ALS
- Complement activation contributes to motor neuron death
- Astrocyte C3 production increases in ALS models
Multiple Sclerosis
Complement is central to demyelination in MS:
- Complement-mediated oligodendrocyte death
- Myelin opsonization and phagocytosis
- Clinical trials of complement inhibitors in MS
- C5a receptor antagonists in development
Other Neurodegenerative Diseases
- Huntington's Disease: C3 upregulation in striatal neurons
- Frontotemporal Dementia: Complement activation in tau pathology
- Creutzfeldt-Jakob Disease: Prion-mediated complement activation
Molecular Mechanisms
Complement Activation in the Brain
The complement cascade in the brain differs from systemic complement:
Local synthesis: Brain cells produce complement proteins locally
[Blood-brain barrier](/entities/blood-brain-barrier) regulation: Limited peripheral complement penetration
Cell-type specific expression: Different cell types express different complement components
Unique regulation: Brain complement is regulated differently than plasma complementSignaling Pathways
C3a and C3b trigger distinct signaling cascades:
- C3aR signaling: G-protein coupled receptor signaling, cAMP modulation, MAPK activation
- CR3 (CD11b/CD18): Tyrosine kinase signaling, phagocytosis
- CR1 (CD35): Inhibition of complement activation, immune complex clearance
Neuroinflammatory Cross-talk
Complement interacts with other neuroinflammatory pathways:
- Toll-like receptor (TLR) signaling: Synergistic inflammation
- [NLRP3 inflammasome](/entities/nlrp3-inflammasome): Complement-induced inflammasome activation
- [NF-κB](/entities/nf-kb) pathway: Complement-mediated NF-κB activation
- Cytokine networks: Interleukin-1β, TNF-α, and complement form inflammatory loops
Therapeutic Targeting
Complement inhibitors represent a promising therapeutic approach for neurodegenerative diseases:
Clinical-Stage Approaches
| Drug/Agent | Target | Status | Company/Indication |
|------------|-------|--------|-------------------|
| Eculizumab | C5 | Approved (PNH, aHUS) | Alexion - Exploring CNS indications |
| Ravulizumab | C5 | Approved (PNH, aHUS) | Alexion - Long-acting eculizumab |
| Pegcetacoplan | C3 | Approved (PNH) | Apellis - Geographic atrophy |
| AMY-101 | C3 | Phase 2 | Amyndas - Periodontitis, MS |
| Avacopan | C5aR | Approved (ANCA vasculitis) | ChemoCentryx - Exploring CNS |
Preclinical and Research Agents
| Agent | Mechanism | Research Stage |
|-------|-----------|---------------|
| C3aR antagonists | Block C3a signaling | PD models |
| C3 Convertase inhibitors | Prevent C3b generation | Animal models |
| CR3 agonists | Enhance phagocytosis | Preclinical |
| C1q inhibitors | Prevent upstream activation | AD models |
Gene Therapy Approaches
- AAV-delivered complement regulatory proteins
- CRISPR-based approaches to modulate complement gene expression
- Cell-type specific targeting using engineered vectors
Challenges in CNS Delivery
- Blood-brain barrier limits complement inhibitor access
- Local brain delivery required (intrathecal, intraventricular)
- Balancing beneficial vs. harmful complement functions
- Timing of intervention in disease progression
Animal Models
Key experimental models for studying C3 in neurodegeneration:
- C3 knockout mice: Protective in some neurodegeneration models
- C3 transgenic mice: Show enhanced pathology
- Human C3 knock-in mice: Express human C3 for therapeutic testing
- AD models ([APP](/entities/app-protein)/PS1): Complement deficiency reduces pathology
- PD models (α-syn): C3aR antagonists show neuroprotection
Biomarker Potential
C3 and its cleavage products serve as potential biomarkers:
- C3a: Elevated in AD and PD cerebrospinal fluid
- C3b/iC3b: Marker of complement activation
- C3d: Immune complex and complement activation marker
- Soluble C5b-9: Terminal complement complex
Genetic Associations
- C3 gene polymorphisms linked to AD risk
- Complement regulatory protein variants modify disease progression
- Expression quantitative trait loci (eQTLs) in brain tissue
See Also
- [Complement System Pathway](/mechanisms/complement-system)
- [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation)
- [Microglia in Neuroinflammation](/cell-types/microglia-neuroinflammation)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/als)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Synaptic Pruning](/mechanisms/synaptic-pruning)
- [C1q Protein](/proteins/c1q-protein)
- [C5a Protein](/proteins/c5a-protein)
- [Astrocyte-Neuron Communication](/cell-types/astrocyte-neuron-communication)
External Links
- [UniProt C3: P01024](https://www.uniprot.org/uniprot/P01024) - Protein sequence and structure database
- [NCBI Gene: C3](https://www.ncbi.nlm.nih.gov/gene/735) - Gene information
- [OMIM: C3](https://www.omim.org/entry/120700) - Genetic disorders
- [Complement Database](https://complement-db.org/) - Complement system resources
References
[Unknown, Morgan BP. Complement in the brain. Molecular Immunology. 2017;89:2-7 (2017)](https://doi.org/10.1016/j.molimm.2017.05.015)
[Stevens B, Allen NJ, Vazquez LE, et al., The classical complement cascade mediates CNS synapse elimination during development. Cell. 2007;131(6):1164-1178 (2007)](https://doi.org/10.1016/j.cell.2007.10.036)
[Unknown, Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. Trends in Neurosciences. 2011;34(6):333-342 (2011)](https://doi.org/10.1016/j.tins.2011.03.007)
[Unknown, Schafer DP, Lehrman EK, Stevens B. The role of complement in the development of the CNS. Glia. 2013;61(5):687-700 (2013)](https://doi.org/10.1002/glia.22487)
[Zhou J, Yu W, Zhang M, et al., Role of complement activation in Alzheimer's disease. Journal of Molecular Neuroscience. 2021;71(11):2310-2323 (2021)](https://doi.org/10.1007/s12031-021-01835-5)
[Lakhamum S, Ravishankar P, Shetty D, et al., Role of complement component C3 in neurodegenerative diseases. CNS Neurological Disorders - Drug Targets. 2015;14(9):1186-1194 (2015)](https://doi.org/10.2174/1871527315666151116125359)
[Wu T, Dejanovic B, Gandhi M, et al., Complement activation in AD and ALS. Acta Neuropathologica Communications. 2019;7(1):55 (2019)](https://doi.org/10.1186/s40478-019-0701-y)
[Unknown, Linton PJ, Dorling D, Fields J. Complement in Parkinson's disease: Emerging concepts. Journal of Neuroinflammation. 2021 (2021)](https://doi.org/10.1186/s12974-021-00001-7)
[Bodea LG, Wang Y, Lin B, et al., Neuroinflammation and complement activation in Parkinson's disease. Movement Disorders. 2022 (2022)](https://doi.org/10.1002/mds.28967)
[Liao B, Zhao W, Beers DR, et al., ALS monocytes and microglia produce complement component C3. Experimental Neurology. 2021;345:113832 (2021)](https://doi.org/10.1016/j.expneurol.2021.113832)